comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-23 04:57:53 - browse：2728

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Psychedelics group wrestles with new pharma identity
Next article： HHS leader on health, climate change and biopharma emissions

Wikipedia

WSS

NIH confirmation hearing shows politicization of research

First Opinion Podcast: Long Covid needs a new approach

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Robert F. Kennedy is pitching centrism on health, even on abortion

Eli Lilly expects to double planned employment in Boston center

Medicare threatens to cut off funding for HCA's Mission hospital

hotspot

comprehensive

focus

How one medical school became remarkably diverse

Vaccine advisory panel ACIP left half staffed by HHS

Virginia high school admissions case could be legal follow

Beam Therapeutics to lay off 20% of its staff, re

Guidelines to prevent youth baseball injuries need more muscle

What we’ve learned from the Aduhelm mess

In Memoriam: Notable people who died in 2023

The dental labor crisis is a moment of opportunity

Psychedelics group wrestles with new pharma identity

Solve the antibiotic resistance crisis with preventive drugs

explore

Medicare Advantage proposed rates disappoint insurers

HHS leader on health, climate change and biopharma emissions

FDA warns J&J's Abiomed: We will regulate your software

PhRMA lawsuit over Medicare drug price negotiation tossed

Pharmacists can make shortage drugs, but at what cost?

What should King Charles tell the public about his cancer?

knowledge

focus

Wikipedia

explore